Search clinical trials for: Nivolumab Injection [Opdivo]

Total 11426 results

University of California, San Francisco
Bristol-Myers Squibb; National Cancer Institute (NCI)

Completed

Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

HIV/AIDS | Kaposi Sarcoma | Immunosuppression

United States
Momotaro-Gene Inc.
Baylor College of Medicine; Synteract, Inc.

Active, not recruiting

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Malignant Pleural Mesothelioma

United States
Virogin Biotech Canada Ltd

Recruiting

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

Solid Tumor

United States
Tel-Aviv Sourasky Medical Center

Recruiting

Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

B Cell Lymphoma

Israel
Melbourne Health

Active, not recruiting

Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation (NIVALLO)

Haematological Malignancy

Australia
Virogin Biotech Canada Ltd

Recruiting

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Hepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Mesothelioma

United States
TaiRx, Inc.

Recruiting

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Advanced Cancer

Taiwan
Sarcoma Oncology Research Center, LLC
Advenchen Laboratories, LLC

Active, not recruiting

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Soft Tissue Sarcoma | Small Cell Lung Cancer | Non Small Cell Lung Cancer | Solid Tumor, Adult

United States
Assistance Publique - Hôpitaux de Paris
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation (NIVOLEP)

Hepatocellular Carcinoma

France
Gruppo Oncologico del Nord-Ovest

Completed

NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN (NIVACTOR)

Squamous Cell Carcinoma of Head and Neck

Italy
CNBG-Virogin Biotech (Shanghai) Ltd.

Recruiting

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

Metastatic Gastric Cancer

China
St. Petersburg State Pavlov Medical University

Completed

Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma (Nivo40)

Hodgkin Lymphoma

Russian Federation
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

France, Denmark, Netherlands
Sheba Medical Center
Bristol-Myers Squibb; Checkmate Pharmaceuticals

Completed

Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer

Liver Metastases | Colorectal Neoplasms Malignant

Israel
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA)

Malignant Melanoma Stage III

United States, Netherlands, Australia
Herlev and Gentofte Hospital
Bristol-Myers Squibb

Recruiting

Checkpoint Inhibitors and SBRT for mCRPC (CheckPRO)

Prostate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IV

Denmark
HUYABIO International, LLC.
Bristol-Myers Squibb

Recruiting

Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma

Unresectable or Metastatic Melanoma | Progressive Brain Metastasis

Spain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
University Hospital, Strasbourg, France
Bristol-Myers Squibb

Completed

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis (CRIRIN)

Melanoma (Skin)

France
Hospital Israelita Albert Einstein
Bristol-Myers Squibb; Brava

Recruiting

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Uterine Cervical Neoplasms

Brazil
GERCOR - Multidisciplinary Oncology Cooperative...
Bristol-Myers Squibb

Recruiting

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. (NEONIPIGA)

Localized Oesogastric Adenocarcimona | MSI and or dMMR

France
China Medical University Hospital

Recruiting

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Hepatocellular Carcinoma

Taiwan
Inge Marie Svane

Recruiting

Melanoma Metastasized to the Brain and Steroids (MEMBRAINS)

Malignant Melanoma

Denmark
Immatics US, Inc.

Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (ACTengine)

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

United States, Germany
Memgen, Inc.
H. Lee Moffitt Cancer Center and Research Institute; Duke Cancer Institute

Recruiting

MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Solid Tumor | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Advanced Cancer | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
University Hospital Tuebingen

Recruiting

Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26) (IT-PD1)

Leptomeningeal Disease

Germany
Dan Zandberg
Bristol-Myers Squibb

Active, not recruiting

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Withdrawn

SBRT as a Vaccination for Metastatic Melanoma

Metastatic Melanoma

United States
Royal Marsden NHS Foundation Trust

Unknown

A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR) (ADAPTeR)

Renal Cell Carcinoma

United Kingdom
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma (GALAXY-1)

Neoplasms | Antineoplastic Agents | Carcinoma, Squamous

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Bladder Cancer | Urothelial Carcinoma

United States
Amgen

Recruiting

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Melanoma

Italy, Spain, South Africa, Japan, Serbia, Bosnia and Herzegovina, United States, Argentina, Chile, Georgia, Malaysia, Korea, Republic of, France, Germany, Croatia, Thailand, Brazil, Taiwan, Romania, Mexico, Netherlands
howard safran
The Miriam Hospital; Rhode Island Hospital

Terminated

Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease

NSCLC | Lung Cancer | Metastatic Lung Cancer | Non-small Cell Lung Cancer

United States
University Hospital, Tours

Completed

Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer (NIVEAL)

Kidney Cancer | Lung Cancer

France
Augusta University

Terminated

Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer

Small Cell Lung Carcinoma | Small-cell Lung Cancer

United States
Replimune Inc.

Recruiting

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Cancer

United Kingdom, Spain
Replimune Inc.

Recruiting

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

Cancer | NSCLC | Melanoma (Skin) | Microsatellite Instability | Cutaneous Melanoma | Mismatch Repair Deficiency | Non-melanoma Skin Cancer

United States, Spain, France, United Kingdom, Germany
Ontario Clinical Oncology Group (OCOG)
Bristol-Myers Squibb

Active, not recruiting

SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK)

Metastatic Renal Cell Carcinoma

Canada, Australia
GERCOR - Multidisciplinary Oncology Cooperative...
Bristol-Myers Squibb

Recruiting

Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE)

Colorectal Cancer Metastatic | MSI-H Colorectal Cancer

France
Compugen Ltd
Bristol-Myers Squibb

Active, not recruiting

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Breast Cancer | Ovarian Cancer | Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Advanced Cancer | Colo-rectal Cancer | Ovarian Neoplasm | Neoplasm Malignant | Lung Neoplasm

United States
PrECOG, LLC.
Bristol-Myers Squibb

Completed

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807)

Bladder Cancer

United States
Spanish Lung Cancer Group

Completed

Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient (NIVEX)

Non Small Cell Lung Cancer

Spain
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Melanoma

Spain, United States, Italy, Chile, Greece, Argentina
Michael B. Atkins, MD
Bristol-Myers Squibb; Hoosier Cancer Research Network

Active, not recruiting

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

United States
Bristol-Myers Squibb

Completed

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (CheckMate 914)

Carcinoma, Renal Cell

United States, Italy, Brazil, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, France, Germany, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, Singapore, Spain, Switzerland, Turkey, United...
Swiss Group for Clinical Cancer Research

Active, not recruiting

Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

Switzerland
Bayer
Bristol Myers Squibb Co. and Ono Pharmaceutical Co., Ltd

Active, not recruiting

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Solid Tumors

United States, United Kingdom, Belgium, France, Taiwan, Japan, Italy, Korea, Republic of
Nektar Therapeutics

Terminated

A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies (REVEAL)

Melanoma | Sarcoma | Renal Cell Carcinoma | Colorectal Cancer | Triple Negative Breast Cancer | Head and Neck Squamous Cell Carcinoma | Merkel Cell Carcinoma

United States
Medical College of Wisconsin

Terminated

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Lymphoma | Myelodysplastic Syndromes | Acute Leukemia | Chronic Leukemia

United States
Bristol-Myers Squibb

Completed

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Cancer

United States

Search clinical trials for: Nivolumab Injection [Opdivo]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations